1-hydroxy-2-oxo-3-(3-aminopropyl)-3-propyl-1-triazene

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 1-hydroxy-2-oxo-3-(3-aminopropyl)-3-propyl-1-triazene
• 英文别名: (E)-[3-azaniumylpropyl(propyl)amino]-oxido-oxidoiminoazanium
• 化学式: C₆H₁₆N₄O₂
• 分子量: 176.219
• InChiKey: QODRTFHTYGHQMT-CSKARUKUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  90.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-丙基-1,3-丙二胺 在 氧化亚氮 作用下， 以 乙腈 为溶剂， 反应 23.0h， 以82%的产率得到1-hydroxy-2-oxo-3-(3-aminopropyl)-3-propyl-1-triazene
  参考文献：
  名称：

  New nitric oxide-releasing zwitterions derived from polyamines

  摘要：

  The reaction of nitric oxide (NO) with polyamines has been studied, resulting in the discovery of a new type of NO-releasing compound having the structure RN[N(O)NO]-(CH2)xNH2+R' (3). Numerous examples of these zwitterionic polyamine/NO adducts have been prepared and found to be very stable solids which release NO in solution. The new compounds contain as much as 45% NO by weight and are capable of releasing it all at rates which have been shown to vary in a predictable way with structure. The half-lives in buffered aqueous solution at pH 7.4 and 22-degrees-C were shown to vary from extremely short (1.3 min for diamine 8, MeN[N(O)NO]-(CH2)4NH2+Me) to very long (56 h for triamine 18, H2NCH2CH2N[N(O)NO]-CH2CH2NH3+). In general, the longest half-lives were achieved by triamine/NO adducts and derivatives of ethylenediamine (x = 2). For any given value of x, a small increase in the size of R resulted in a relatively large increase in half-life but changes in R' appeared to have little effect. Data are presented which should allow the selection of the proper compounds to achieve a wide range of desired NO generation rates. These NO-containing zwitterions should prove to be important resources in studies of the biology of NO and may also have important pharmaceutical and chemical applications.

  DOI：

  10.1021/jo00058a030

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Substrates for nitric oxide releasing devices
  申请人：Hyde Roderick A.

  公开号：US10080823B2

  公开（公告）日：2018-09-25

  The present disclosure relates to substrates associated with nitric oxide.

  本公开涉及与一氧化氮相关的底物。
• TREATMENT OF FEMALE SEXUAL DYSFUNCTION
  申请人：Asivi, LLC

  公开号：EP1027057A1

  公开（公告）日：2000-08-16
• EP1027057A4
  申请人：——

  公开号：EP1027057A4

  公开（公告）日：2003-01-02
• TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ERECTILE DYSFUNCTION
  申请人：Vivus, Inc.

  公开号：EP1237577A2

  公开（公告）日：2002-09-11